# Karyopharm Therapeutics Inc clinical trials: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Karyopharm Therapeutics Inc as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Karyopharm Therapeutics Inc: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/karyopharm-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 14, 2025 | NCT07215832 | Karyopharm Expanded Access Program for Selinexor | Karyopharm Therapeutics Inc | Not applicable | Available | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215832) |
| August 8, 2023 | NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Karyopharm Therapeutics Inc | Phase 2 | Recruiting | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05980806) |
| November 10, 2022 | NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Karyopharm Therapeutics Inc | Phase 3 | Active not recruiting | Endometrial Cancer | 257 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05611931) |
| April 22, 2021 | NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated... | Karyopharm Therapeutics Inc | Phase 2 | Terminated | Metastatic Colorectal Cancer | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04854434) |
| February 24, 2021 | NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | Karyopharm Therapeutics Inc | Phase 2 | Terminated | Locally Advanced Unresectable or Metastatic Melanoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04768881) |
| October 29, 2020 | NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse... | Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04607772) |
| September 24, 2020 | NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Karyopharm Therapeutics Inc | Phase 2 | Active not recruiting | Myelofibrosis | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04562870) |
| September 24, 2020 | NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Karyopharm Therapeutics Inc | Phase 3 | Active not recruiting | Myelofibrosis | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04562389) |
| June 22, 2020 | NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse... | Karyopharm Therapeutics Inc | Phase 2/3 | Active not recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma | 501 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04442022) |
| June 9, 2020 | NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Karyopharm Therapeutics Inc | Phase 1/2 | Terminated | Glioblastoma Multiforme | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04421378) |
| June 4, 2020 | NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in... | Karyopharm Therapeutics Inc | Phase 2 | Recruiting | Multiple Myeloma, Refractory | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04414475) |
| April 21, 2020 | NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | Coronavirus Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04355676) |
| April 16, 2020 | NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | Karyopharm Therapeutics Inc | Phase 2 | Completed | Coronavirus Infection | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04349098) |
| February 5, 2020 | NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor... | Karyopharm Therapeutics Inc | Phase 1/2 | Completed | Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04256707) |
| June 13, 2018 | NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer \[SIENDO\] | Karyopharm Therapeutics Inc | Phase 3 | Completed | Endometrial Cancer | 263 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03555422) |
| April 12, 2017 | NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | Karyopharm Therapeutics Inc | Phase 3 | Completed | Multiple Myeloma | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03110562) |
| March 8, 2016 | NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | Karyopharm Therapeutics Inc | Phase 1 | Terminated | Solid Tumors, NHL | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02702492) |
| January 7, 2016 | NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Karyopharm Therapeutics Inc | Phase 1/2 | Completed | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant... | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02649790) |
| December 11, 2015 | NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02628704) |
| November 17, 2015 | NCT02606461 | Selinexor in Advanced Liposarcoma | Karyopharm Therapeutics Inc | Phase 2/3 | Completed | Dedifferentiated Liposarcoma | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02606461) |
| May 1, 2015 | NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | Karyopharm Therapeutics Inc | Phase 1 | Terminated | Healthy | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431364) |
| May 1, 2015 | NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | Karyopharm Therapeutics Inc | Phase 2 | Withdrawn | Myelodysplastic Syndrome | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431351) |
| March 17, 2015 | NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02389543) |
| February 20, 2015 | NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | Karyopharm Therapeutics Inc | Phase 1/2 | Withdrawn | Diabetic Foot Ulcers | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02367690) |
| January 21, 2015 | NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Karyopharm Therapeutics Inc | Phase 1/2 | Recruiting | Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02343042) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 7 |
| Phase 2 | 18 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Terminated | 10 |
| Withdrawn | 6 |
| Active not recruiting | 5 |
| Recruiting | 3 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 9 |
| Recurrence | 5 |
| Colorectal Neoplasms | 4 |
| Endometrial Neoplasms | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Primary Myelofibrosis | 4 |
| Glioblastoma | 3 |
| Lymphoma, T-Cell, Peripheral | 3 |
| Melanoma | 3 |
| Leukemia, Myeloid, Acute | 2 |
| Myelodysplastic Syndromes | 2 |
| Sarcoma | 2 |
| Carcinoma, Squamous Cell | 2 |
| Coronavirus Infections | 2 |
| COVID-19 | 2 |
| Lymphoma, T-Cell, Cutaneous | 2 |
| Ovarian Neoplasms | 1 |
| Uterine Cervical Neoplasms | 1 |
| Liposarcoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma | 1 |
| Uterine Neoplasms | 1 |
| Neoplasms by Site | 1 |
| Neoplasms | 1 |
| Uterine Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Product design firms in the United States](https://specstream.ai/data/businesses/product-design-firms/united-states)
- [Plastic manufacturers in the United States](https://specstream.ai/data/businesses/plastic-manufacturers/united-states)
- [Pediatric cardiology practices in the United States](https://specstream.ai/data/businesses/pediatric-cardiology-practices/united-states)
